Combination therapy with BRMs in cancer and infectious diseases

Enrico Garaci, Francesca Pica, Guido Rasi, Anna T. Palamara, Cartesio Favalli

Research output: Contribution to journalArticlepeer-review


In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.

Original languageEnglish
Pages (from-to)103-116
Number of pages14
JournalMechanisms of Ageing and Development
Issue number1-3
Publication statusPublished - Jun 1997


  • Biological response modifiers (BRMs)
  • Infectious diseases
  • Thymosin α-1

ASJC Scopus subject areas

  • Ageing
  • Biochemistry
  • Developmental Biology
  • Developmental Neuroscience


Dive into the research topics of 'Combination therapy with BRMs in cancer and infectious diseases'. Together they form a unique fingerprint.

Cite this